WO2016108180A3 - Process for formulating acid stabilized oral bacterial vaccine - Google Patents

Process for formulating acid stabilized oral bacterial vaccine Download PDF

Info

Publication number
WO2016108180A3
WO2016108180A3 PCT/IB2015/060022 IB2015060022W WO2016108180A3 WO 2016108180 A3 WO2016108180 A3 WO 2016108180A3 IB 2015060022 W IB2015060022 W IB 2015060022W WO 2016108180 A3 WO2016108180 A3 WO 2016108180A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral bacterial
bacterial vaccine
formulating
acid stabilized
stabilized oral
Prior art date
Application number
PCT/IB2015/060022
Other languages
French (fr)
Other versions
WO2016108180A2 (en
Inventor
Nitin Saigal
Vibhu KANCHAN
Tarun Sharma
Deepa SIKRIWAL
Neeraj Joshi
Davinder Gill
Zimra Israel
Original Assignee
Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. filed Critical Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd.
Priority to BR112017012102-6A priority Critical patent/BR112017012102A2/en
Priority to KR1020177018207A priority patent/KR20170102253A/en
Priority to RU2017122801A priority patent/RU2017122801A/en
Priority to CN201580067254.8A priority patent/CN106999563A/en
Publication of WO2016108180A2 publication Critical patent/WO2016108180A2/en
Publication of WO2016108180A3 publication Critical patent/WO2016108180A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

A process for formulating an oral bacterial vaccine comprising whole cell inactivated Vibrio cholerae combined with enteric coated recombinant cholera toxin. This vaccine provides protection against diarrhoea caused by various bacteria, including V. cholera, Enterotoxigenic Escherichia coli (ETEC).
PCT/IB2015/060022 2014-12-31 2015-12-29 Process for formulating acid stabilized oral bacterial vaccine WO2016108180A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BR112017012102-6A BR112017012102A2 (en) 2014-12-31 2015-12-29 process for formulating an acid-stabilized oral bacterial vaccine
KR1020177018207A KR20170102253A (en) 2014-12-31 2015-12-29 Process for formulating acid stabilized oral bacterial vaccine
RU2017122801A RU2017122801A (en) 2014-12-31 2015-12-29 METHOD FOR ACID RESISTANT ORAL BACTERIAL VACCINE
CN201580067254.8A CN106999563A (en) 2014-12-31 2015-12-29 Method for the stable oral bacterial vaccine of preparating acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4054/DEL/2014 2014-12-31
IN4054DE2014 IN2014DE04054A (en) 2014-12-31 2015-12-29

Publications (2)

Publication Number Publication Date
WO2016108180A2 WO2016108180A2 (en) 2016-07-07
WO2016108180A3 true WO2016108180A3 (en) 2016-09-09

Family

ID=56285110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/060022 WO2016108180A2 (en) 2014-12-31 2015-12-29 Process for formulating acid stabilized oral bacterial vaccine

Country Status (6)

Country Link
KR (1) KR20170102253A (en)
CN (1) CN106999563A (en)
BR (1) BR112017012102A2 (en)
IN (1) IN2014DE04054A (en)
RU (1) RU2017122801A (en)
WO (1) WO2016108180A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013148258A1 (en) * 2012-03-29 2013-10-03 Jerome Schentag Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476929A (en) * 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013148258A1 (en) * 2012-03-29 2013-10-03 Jerome Schentag Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHMED ET AL.: "Thermal Stability of an Oral Killed-Cholera-Whole- Cell Vaccine Containing Recombinant B-Subunit of Cholera Toxin", MICROBIOLOGY & IMMUNOLOGY, vol. 38, no. 11, 1994, pages 837 - 842 *
BUNDELL ET AL.: "Protection of rats against cholera toxin and cholera-like enterotoxins by immunization with enteric-coated cholera toxin", ANNALS OF TROPICAL PAEDIATRICS, vol. 6, no. 3, 1986, pages 199 - 204 *
SVENNERHOLM: "From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development", INDIAN JOURNAL OF MEDICAL RESEARCH, vol. 133, 2011, pages 188 - 196 *

Also Published As

Publication number Publication date
CN106999563A (en) 2017-08-01
KR20170102253A (en) 2017-09-08
WO2016108180A2 (en) 2016-07-07
RU2017122801A3 (en) 2018-12-28
IN2014DE04054A (en) 2016-07-08
BR112017012102A2 (en) 2018-01-23
RU2017122801A (en) 2018-12-28

Similar Documents

Publication Publication Date Title
AU2015274647C1 (en) Protease-cleavage resistant, Shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
IL265737A (en) Compositions comprising a non-pathogenic bacteria and methods for protecting plant and animal hosts from fungal, bacterial and viral diseases
MY186542A (en) Genetically engineered microorganisms for the production of chorismate-derived products
PH12016502003A1 (en) Novel bacteriophage and composition containing same
WO2016077832A3 (en) PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
PT2477649T (en) Vaccine against cholera and enterotoxigenic e. coli (etec) diarrhea
AU2018301662A1 (en) Purified 2,5-furandicarboxylic acid pathway products
EP3255140A4 (en) Lactic acid bacteria, natural immunoactivator and infection preventative/therapeutic derived from said lactic acid bacteria, and food/beverage
MX2017012073A (en) Minocycline compounds for biodefense.
EP3784220A4 (en) Edible plant exosome-like nanovectors for vaccination
WO2020061443A3 (en) Methods of making and using universal centralized influenza vaccine genes
MX2017003294A (en) Quinoline carboxamides for use in the treatment of multiple myeloma.
EP3764968A4 (en) Patient transfer system
EP3776846A4 (en) Heat exchange system
WO2016108180A3 (en) Process for formulating acid stabilized oral bacterial vaccine
WO2014128555A3 (en) Vaccine
EP3945788A4 (en) Increasing plant transformability by cytotype transfer
EP3936135A4 (en) Nucleic acid delivery complex
EP3752089A4 (en) Peracetic acid vapor sterilization system
WO2018179003A3 (en) Enteric fever vaccine based on outer membrane vesicles from two different strains of typhoidal salmonella species
EP3735233A4 (en) Artemisinic acid glycoconjugate compounds, process for preparation and use thereof
BR112016018257A2 (en) method to produce an l-amino acid
WO2018029590A3 (en) An autoclave sterilisation process for primary containers made of glass
EP3392291A4 (en) Vaccine adjuvant composition based on amphiphilic polyamino acid polymer, containing squalene
IL283609A (en) Oral therapy using 6,8-bis-benzylthio-octanoic acid

Legal Events

Date Code Title Description
REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017012102

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017122801

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20177018207

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 112017012102

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170607

122 Ep: pct application non-entry in european phase

Ref document number: 15875346

Country of ref document: EP

Kind code of ref document: A2